Peptides and Muscle Growth: Which Ones Actually Have Evidence Behind Them

Four names come up in almost every muscle conversation, and they’re Tesamorelin, CJC-1295 No-DAC, Ipamorelin and IGF-1 LR3. Four more show up on the recovery side, which are BPC-157, TB-500, GHK-Cu and KPV. They get listed together like they all do the same job, and they don’t. The evidence behind them isn’t even close to being in the same league.

Growth hormone going up is not the same as muscle going on

This is where most peptide articles lose me. A compound raises growth hormone, so somebody calls it a muscle-building peptide and everyone repeats it.

That’s a big jump to make. Growth hormone affects IGF-1, fat metabolism, fluid balance and body composition without automatically producing a meaningful change in skeletal muscle size or strength.

The term lean mass causes the same problem. Lean mass isn’t pure muscle. It’s every tissue in your body that isn’t fat, and that includes water.

So when I read a study, I want to know which of these things actually moved:

• Did visceral fat go down?
• Did lean mass go up?
• Did actual muscle size change?
• Did strength improve?
• Did the study measure recovery at all?
• Or did GH and IGF-1 simply rise on a blood panel?

Those are six different findings, and they get reported online as if they’re one finding. With that out of the way, let’s go through the compounds.

Tesamorelin has the strongest human file of the group

Tesamorelin is a growth hormone-releasing hormone analogue. Rather than introducing growth hormone from the outside, it signals the pituitary to release more of your own, and IGF-1 tends to rise downstream of that.

What separates Tesamorelin from almost everything else discussed online is that we have substantial randomized human data on it.

Large randomized trials studied Tesamorelin in adults with excess abdominal visceral fat. In one major trial, visceral fat dropped by roughly 15% over 26 weeks while the placebo group actually gained visceral fat, and other trials have reported reductions in the same range. [CITE] A separate randomized study found a significant reduction in visceral abdominal fat along with a reduction in liver fat. [CITE]

That’s a completely different level of evidence than the rest of this article deals with, and it’s worth sitting with for a second before you read anything below it.

Why lifters read those trials differently

Nobody looking at Tesamorelin is trying to become a professional bodybuilder. They’re looking at a combination of higher endogenous GH signaling, higher IGF-1, less visceral fat and better overall body composition, and that combination gets a lot more interesting once you’re past 40.

What we don’t have is a controlled study that put trained lifters on Tesamorelin and measured ten pounds of new muscle. That study doesn’t exist, so I’m not going to pretend it does.

If somebody told me their real goal was getting leaner while paying attention to the GH and IGF-1 side of body composition, I’d understand immediately why Tesamorelin ended up on their list.

The pulse argument for CJC No-DAC and Ipamorelin

There are two completely different conversations happening under the name CJC-1295, and mixing them up is how people end up confused. You have CJC-1295 with DAC, and you have CJC-1295 without DAC, which usually means Mod GRF 1-29.

I’m far more interested in the No-DAC version when the subject is training, sleep and recovery, and the reason comes down to how your body normally handles growth hormone.

GH doesn’t come out at one steady level all day. It comes out in pulses, and one of the largest normally happens during the first part of sleep. The DAC version is built to stay active for a long stretch, which produces a prolonged elevation in GH and IGF-1. The No-DAC version is short acting, so the idea is to create a temporary GHRH signal instead of holding the system stimulated for days.

The catch that usually gets skipped

The strong human CJC research was done with the DAC version, and it showed prolonged increases in growth hormone and IGF-1. The compound commonly sold as CJC No-DAC or Mod GRF 1-29 doesn’t carry that same body of controlled human outcome research.

Nobody has clinically demonstrated that No-DAC builds muscle. The interest is in the physiology, meaning a shorter signal and a pulse instead of days of elevation. That physiology gets more interesting once you understand what Ipamorelin is doing.

Ipamorelin comes at it from a different receptor

CJC No-DAC works through the GHRH receptor and Ipamorelin works through the ghrelin receptor. Both can tell the pituitary to release growth hormone, but they arrive from two different directions.

We actually have human pharmacology data on Ipamorelin. In healthy male volunteers, it produced a single GH episode that peaked fairly quickly and then declined back toward negligible levels. [CITE] That behavior looks much more like a pulse than a sustained elevation, which is exactly why the two get paired.

Stack them and you’re stimulating the GH system through two separate pathways in roughly the same window. Mechanistically that makes sense to me. What I won’t tell you is that a controlled human trial showed the pair producing a specific amount of muscle, because that trial doesn’t exist either.

This is probably the best example in the whole category of a combination where the mechanism is genuinely interesting and the performance research hasn’t caught up yet. If evidence quality is what you care about most, Tesamorelin wins that comparison without much of an argument.

IGF-1 LR3 sits closest to the actual growth signal

IGF-1 stands for insulin-like growth factor 1, and muscle cells are extremely responsive to it. It’s involved in protein synthesis, satellite cell activity, cell growth and tissue repair, which is why bodybuilding has been fascinated with it for decades.

IGF-1 LR3 is a modified analogue of that molecule. It was altered so that it interacts differently with IGF-binding proteins and stays biologically available longer than native IGF-1, which is where the reputation came from. On paper it sounds purpose-built for muscle growth.

There are no controlled human bodybuilding trials showing that IGF-1 LR3 builds muscle. There are no controlled human trials on how much strength it adds, and there’s no established clinical protocol. Most of what circulates online traces back to animal research, cell research, extrapolation from native IGF-1 biology and gym experience.

Both of these things are true at the same time, and neither one cancels the other. The GH secretagogues work upstream while IGF-1 LR3 operates much closer to the growth signal itself, which makes it the most interesting compound here biologically. It’s also the one where the missing human safety and outcome data should weigh on you the most.

Recovery is what actually stops most people

You can run a perfect program and keep your diet dialed in and have every growth pathway working in your favor, and none of it matters if your shoulder keeps you off pressing for three months. That’s where the second group of peptides enters the conversation.

BPC-157

BPC-157 is probably the most famous name in this entire category. The published research covers blood vessel formation, tendon healing, gastrointestinal injury, nerve injury and several other repair pathways, and it’s broad enough that I understand the attention it gets.

Almost all of it is animal research. We don’t have a completed controlled human trial showing that BPC-157 heals a torn tendon or ligament, and that needs to be said plainly rather than buried at the bottom of an article.

I’ve followed this compound closely for years and I know plenty of people who are convinced by it. That’s still not a trial. There’s a lot of biological smoke here and we haven’t found the human fire yet.

TB-500

TB-500 is the other name you hear constantly alongside BPC-157. It’s associated with Thymosin Beta-4, a naturally occurring peptide involved in cell migration, blood vessel formation, inflammation and tissue remodeling.

We finally got something that had been missing for years, which is a direct head-to-head experiment. In 2026, researchers compared BPC-157, TB-500 and the combination in rats after Achilles tendon transection and surgical repair. The TB-500 group showed a statistically significant improvement in maximum load to failure compared with controls, along with significant improvements in several measures of tendon structure and collagen organization. The BPC-157 group improved numerically on several outcomes but didn’t reach statistical significance on the main total scores. [CITE] Combining the two didn’t outperform either one on its own. [CITE]

Before anyone turns that into “TB-500 beats BPC-157,” remember what the study was. Thirty-two rats, not thirty-two athletes. It’s still one of the more useful recovery studies I’ve read recently, because somebody finally put both compounds in the same experiment instead of comparing across studies that were never designed to be compared.

GHK-Cu

Most people hear GHK-Cu and think about skin, wrinkles and hair, which is only part of the picture. It’s a naturally occurring copper-binding peptide involved in tissue remodeling and wound repair, and researchers have also looked at it in tendon and ligament models.

Training creates damage, and repairing that damage runs through collagen formation and remodeling of the extracellular matrix around the tissue. That’s the overlap that makes GHK-Cu relevant to a recovery discussion rather than a cosmetics discussion. It isn’t a proven human tendon therapy and I’m not going to call it one.

KPV

KPV is the odd one out here. It’s a three-amino-acid fragment derived from alpha-MSH, and the research interest is almost entirely about inflammation, where it has shown anti-inflammatory activity in preclinical models.

Inflammation isn’t automatically the enemy. You need an inflammatory response to adapt to training and repair tissue at all. The interest sits with inflammation that becomes excessive or chronic, which is why I think of KPV as a different tool for a different job rather than a muscle peptide. Human performance research on it is very limited.

Past 40, the whole question changes

At 25 I cared about one thing, which was more muscle. I’m in my fifties now and I still want muscle and I still want to look good, but I’m also looking twenty years down the road.

Muscle sits near the top of the list of things I don’t want to lose, because eventually this stops being about how your arms fill out a T-shirt. It becomes about whether you can get off the floor without help, climb a flight of stairs, carry your own luggage, and whether a small fall turns into a major event.

The real question is whether you’re still training at 70 or sitting in a chair watching everyone else do it. That’s a completely different way to think about the same set of compounds.

Where I’d start if I were you

Start with the problem you’re trying to solve instead of the compound somebody mentioned on a podcast.

If visceral fat and body composition are the issue, Tesamorelin is the one with actual randomized human trials behind it, so that’s where the reading should start. If you’re interested in your own GH pulses, sleep and recovery, then CJC No-DAC and Ipamorelin are worth understanding, as long as you understand the evidence gap along with the mechanism. If you want the direct growth-factor side of the conversation, learn what IGF-1 actually does before you go anywhere near IGF-1 LR3.

And if the thing stopping you is that something always hurts, then recovery is your real problem, which puts BPC-157, TB-500, GHK-Cu and KPV in a completely different category from everything above them.

There’s no single muscle peptide. Collecting names because they all appeared on the same list is how people spend a lot of money without learning anything. Building muscle matters, and staying healthy enough to keep training long enough to hold onto it matters more.

What to read next

If you want to understand why I keep coming back to shorter GH pulses instead of asking which compound keeps GH elevated the longest, read Growth Hormone, Sleep and Recovery: The DAC Question.

If injuries are the bigger issue for you, start with Tendon and Tissue Repair: What the Evidence Actually Supports.

This article is an educational discussion of published research, mechanisms and my own opinions. Several compounds discussed here have limited or no controlled human evidence and are not FDA approved for muscle growth or athletic performance.

This is not medical advice. Research use only.